POZELIMAB
UNII 0JJ21K6L2I

Substance Identification & Data

This profile provides standardized clinical and technical data for Pozelimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 0JJ21K6L2I.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2096328-94-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

0JJ21K6L2I

CAS Registry Number

2096328-94-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

POZELIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

0JJ21K6L2I

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C166423

National Cancer Institute reference terminology for clinical and research data.

INN ID

10945

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FG-06

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Pozelimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

POZELIMAB

POZELIMAB-BBFG

Common Names & Synonyms

POZELIMAB [INN]

POZELIMAB [USAN]

POZELIMAB [WHO-DD]

POZELIMAB BBFG [WHO-DD]

Brand / Trade Names

VEOPOZ

Systematic Nomenclature

IMMUNOGLOBULIN G4 (228-PROLINE), ANTI-(HUMAN COMPLEMENT C5) (HUMAN MONOCLONAL REGN3918 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN3918 .KAPPA.-CHAIN, DIMER

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS C5 (COMPLEMENT C5)), HOMO SAPIENS MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN HOMO SAPIENS (1-447) (VH (HOMO SAPIENS IGHV4-59*02 (94.8%)-(IGHD)-IGHJ4*01 (100%)) (8.7.14) (1-120)-HOMO SAPIENS IGHG4*01 (CH1 (121-218), HINGE S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)), (134-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HOMO SAPIENS (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-6*01 (96.8%)-IGKJ1*01 (100%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214'))DIMER (226-226'':229-229'')-BISDISULFIDE

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS COMPLEMENT C5)HUMAN MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-447) (HOMO SAPIENS VH (IGHV4-59*02 (95%) (IGHD)-IGHJ4*01) (8.7.14) (1-120)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(228))) (121-447)) (134-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-214') (HOMO SAPIENS V-KAPPA (IGKV1-6*01 (97%) IGKJ1*01)(6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (226-226'':229-229'')-BISDISULFIDE

SYS